• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.

作者信息

Hurley M J, Mash D C, Jenner P

机构信息

Neurology Department, University of Miami School of Medicine, Miami, FL, USA.

出版信息

J Neural Transm (Vienna). 2003 Nov;110(11):1279-88. doi: 10.1007/s00702-003-0033-7.

DOI:10.1007/s00702-003-0033-7
PMID:14628192
Abstract

Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of the cannabinoid CB(1) receptor mRNA in post-mortem brain tissue obtained from normal subjects and patients dying with Parkinson's disease. CB(1) receptor mRNA was detected in striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus, substantia nigra) brain regions. In parkinsonian tissue the level of CB(1) receptor mRNA was decreased in the caudate nucleus, anterior dorsal putamen and external segment of the globus pallidus, but remained unchanged in the other brain areas examined. These results show that CB(1) receptor mRNA expression was altered in Parkinson's disease (though the effects of drug treatment can not be ruled out) and indicate that cannabinoid CB(1) receptor mRNA expression was affected by alterations in dopaminergic systems.

摘要

相似文献

1
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.
J Neural Transm (Vienna). 2003 Nov;110(11):1279-88. doi: 10.1007/s00702-003-0033-7.
2
Adenosine A(2A) receptor mRNA expression in Parkinson's disease.帕金森病中腺苷A(2A)受体mRNA的表达
Neurosci Lett. 2000 Sep 8;291(1):54-8. doi: 10.1016/s0304-3940(00)01371-9.
3
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease.
Brain Res Mol Brain Res. 2001 Mar 5;87(2):271-9. doi: 10.1016/s0169-328x(01)00022-5.
4
Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats.成年大鼠基底神经节中5-羟色胺2C受体信使核糖核酸的表达模式
J Comp Neurol. 1997 Jul 28;384(2):233-47.
5
Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease.正常人基底神经节和帕金森病中谷氨酸脱羧酶-67信使核糖核酸的表达
Neuroscience. 1996 Nov;75(2):389-406. doi: 10.1016/0306-4522(96)00299-0.
6
Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats.6-OHDA 损毁大鼠基底节区 CB1 cannabinoid 受体的时程变化:一种可能的结构特异性可塑性过程。
PLoS One. 2013 Oct 8;8(10):e76874. doi: 10.1371/journal.pone.0076874. eCollection 2013.
7
Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.亨廷顿舞蹈病患者苍白球中大麻素(CB(1))、γ-氨基丁酸A(GABA(A))和γ-氨基丁酸B(GABA(B))受体亚基的变化
J Chem Neuroanat. 2009 Jul;37(4):266-81. doi: 10.1016/j.jchemneu.2009.02.001. Epub 2009 Feb 21.
8
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.帕金森综合征患者及经1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的狨猴基底神经节中,大麻素CB1受体结合增加及GTP结合蛋白激活。
Eur J Neurosci. 2001 Dec;14(11):1827-32. doi: 10.1046/j.0953-816x.2001.01812.x.
9
Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.健康对照者和帕金森病患者基底神经节与额叶皮质中组胺H(3)受体的分布及调节
Neurobiol Dis. 2001 Aug;8(4):707-16. doi: 10.1006/nbdi.2001.0413.
10
Calbindin-D28k in the basal ganglia of patients with parkinsonism.帕金森综合征患者基底神经节中的钙结合蛋白-D28k
Ann Neurol. 1992 Oct;32(4):543-50. doi: 10.1002/ana.410320410.

引用本文的文献

1
Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.大麻素:在神经系统疾病和精神障碍中的作用
Int J Mol Sci. 2024 Dec 27;26(1):152. doi: 10.3390/ijms26010152.
2
Cannabinoids' Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases.大麻素在神经退行性疾病中调节中枢和外周免疫的作用。
Int J Mol Sci. 2024 Jun 10;25(12):6402. doi: 10.3390/ijms25126402.
3
The Expression and Functionality of CBR-NMDAR Complexes Are Decreased in A Parkinson's Disease Model.帕金森病模型中 CBR-NMDAR 复合物的表达和功能降低。
Int J Mol Sci. 2024 Mar 5;25(5):3021. doi: 10.3390/ijms25053021.
4
M3 Receptor Pathway Stimulates Rapid Transcription of the CB1 Receptor Activation through Calcium Signalling and the CNR1 Gene Promoter.M3 受体途径通过钙信号和 CNR1 基因启动子刺激 CB1 受体激活的快速转录。
Int J Mol Sci. 2023 Jan 9;24(2):1308. doi: 10.3390/ijms24021308.
5
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice.植物大麻素和基于大麻的产品作为神经退行性疾病的替代药物治疗:从假设到临床实践
Front Cell Neurosci. 2022 May 30;16:917164. doi: 10.3389/fncel.2022.917164. eCollection 2022.
6
Medicinal Cannabis and Central Nervous System Disorders.药用大麻与中枢神经系统疾病
Front Pharmacol. 2022 Apr 21;13:881810. doi: 10.3389/fphar.2022.881810. eCollection 2022.
7
Cannabinoid Receptor 1 Is Required for Neurodevelopment of Striosome-Dendron Bouquets.大麻素受体 1 是纹状体树突花束神经发育所必需的。
eNeuro. 2022 Apr 11;9(2). doi: 10.1523/ENEURO.0318-21.2022. Print 2022 Mar-Apr.
8
Cannabinoids: Therapeutic Use in Clinical Practice.大麻素:临床实践中的治疗用途。
Int J Mol Sci. 2022 Mar 19;23(6):3344. doi: 10.3390/ijms23063344.
9
Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.病毒介导的α-突触核蛋白在大鼠脑中过表达后内源性大麻素系统的时程变化。
Molecules. 2022 Jan 14;27(2):507. doi: 10.3390/molecules27020507.
10
Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment.大麻素类药物相关的神经保护作用作为一种对抗化疗引起的认知障碍的潜在治疗工具。
Front Pharmacol. 2021 Nov 12;12:734613. doi: 10.3389/fphar.2021.734613. eCollection 2021.